Akebia Therapeutics Announces Collaboration Partner’s Positive Top-line Results of Phase 3 Clinical Study of Riona® (ferric citrate hydrate) in Adult Patients with Iron Deficiency Anemia in Japan

18

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Akebia Therapeutics, Inc. (Nasdaq: AKBA), today announced that its collaboration partner, Japan Tobacco, Inc. (JT) and its subsidiary Torii Pharmaceutical Co., Ltd. (Torii), reported positive top-line results from a pivotal Phase 3 comparative study evaluating Riona® Tablets 250mg (generic name in Japan: ferric citrate hydrate) for the treatment of iron deficiency anemia (IDA) in adult patients in Japan. JT and Torii hold the exclusive rights to develop and ….

 

 

 

 

http://www.businesswire.com/news/home/20190710005225/en/Akebia-Therapeutics-Announces-Collaboration-Partner%E2%80%99s-Positive-Top-line

 

- Advertisement -